MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas

Purpose Knowledge of biological behavior is crucial for clinical management of functioning pituitary macroadenomas. For recurrent cases unresponsive to standard treatment, temozolomide (TMZ) has been used as a therapeutic alternative. MGMT (O6-methyl-guanine-DNA methyltransferase) and MSH6 (mutS hom...

Full description

Saved in:
Bibliographic Details
Published in:Pituitary 2017-12, Vol.20 (6), p.643-653
Main Authors: Micko, Alexander S. G., Wöhrer, Adelheid, Höftberger, Romana, Vila, Greisa, Marosi, Christine, Knosp, Engelbert, Wolfsberger, Stefan
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents, Alkylating - therapeutic use
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
DNA methyltransferase
DNA Modification Methylases - metabolism
DNA Repair Enzymes - metabolism
DNA-Binding Proteins - metabolism
Endocrinology
Female
Guanine
Human Physiology
Humans
Invasiveness
Male
Medicine
Medicine & Public Health
Middle Aged
MSH6 protein
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - immunology
Neoplasm Recurrence, Local - metabolism
O-Methylguanine-DNA Methyltransferase - metabolism
O6-methylguanine-DNA methyltransferase
Pituitary
Pituitary Neoplasms - drug therapy
Pituitary Neoplasms - immunology
Pituitary Neoplasms - metabolism
Remission
Retrospective Studies
Temozolomide
Tumor Suppressor Proteins - metabolism
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Knowledge of biological behavior is crucial for clinical management of functioning pituitary macroadenomas. For recurrent cases unresponsive to standard treatment, temozolomide (TMZ) has been used as a therapeutic alternative. MGMT (O6-methyl-guanine-DNA methyltransferase) and MSH6 (mutS homolog 6) immunoexpression have been linked to the response to TMZ treatment and MGMT immunoexpression has been additionally linked to early recurrence of non-functioning pituitary adenomas. The aim of this study was to assess the prognostic value of MGMT and MSH6 immunoexpression for aggressive functioning pituitary adenomas. Methods The study cohort comprised a single center series of 76 patients who underwent an operation for functioning pituitary macroadenoma. We retrospectively compared 38 patients with postoperative persistent or recurrent disease with another set of 38 patients who were in endocrine remission. Results Low-to-moderate MGMT immunoexpression (
ISSN:1386-341X
1573-7403
DOI:10.1007/s11102-017-0829-3